Achieved three major catalysts to drive future growth:Launched the pediatric indication of Afrezza® following FDA approvalFUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKDPositive nintedanib DPI Phase 1b data in IPF patients validates continued Phase 2 advancementEncouraging early momentum in Afrezza pediatric launch1 in 3 of the top 100 pediatric insulin writers have prescribed Q2 2026 total revenues of $109.4M, +43% vs. Q2 2025Conference call and webcast today at 4:30 p.m. ET DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- MannKindCorporation(Nasdaq:MNKD)